Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.